Project Grant R01CA300681
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$514K
Federal Agency
National Cancer Institute
Awardee
Sanford Research (E6KZG3MNE1D5)
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
South Dakota, USA
Similar Awards
This $540,090 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Regents of the University of California, San Francisco (UCSF). The 5-year grant, effective April 1, 2025, will fund research to characterize the biological basis of distinct epigenetic subtypes of osteosarcoma, a highly complex and genomically heterogeneous bone cancer, and identify subtype-specific vulnerabilities that could inform the...
This $107,948 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research conducted by Case Western Reserve University (CWRU) to study the epigenetic factors driving lung metastasis in osteosarcoma. The research aims to define the "metastasis enabling circuitry" by characterizing the transcription factors and chromatin state changes that promote lung colonization in osteosarcoma. Specifically, the study will investigate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013 to Sanford Research, a non-profit research organization, to develop and characterize genetically engineered mouse models (GEMMs) that replicate key features of human high-risk rhabdomyosarcoma (RMS). The overarching objective is to explore the Notch1 signaling pathway as both a driver and therapeutic target for this aggressive pediatric soft tissue sarcoma. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $452,549.00 to Emory University to conduct research on targeting intrinsic and extrinsic features of MYC-driven osteosarcoma. The key objectives are to:
Comprehensively characterize and genetically perturb cross-species molecular features of MYC-hyperactivated human and murine osteosarcoma tumors to identify intrinsic and extrinsic signatures and cell-cell...
The Department of the Army Medical Command awarded a $1,750,524 project grant to Dana-Farber Cancer Institute, Inc. for research on treatment options for metastatic osteosarcoma. The grant was awarded on August 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research through July 31, 2025.
The Military Medical Research and Development program aims to transform health care for service members and the public through innovative biomedical...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $218,068 to St. Jude Children's Research Hospital Inc. to study the impact of bidirectional signaling between megakaryocytes (cells that produce platelets) and osteosarcoma cells on metastasis. The research aims to understand how interactions between osteosarcoma and megakaryocytes within the bone microenvironment influence tumor progression and metastasis. Specific objectives...
The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $210,789 Project Grant to the Texas A&M University System Health Science Center to conduct research on a DKK-1 targeting antisense therapy for osteosarcoma. The funding will support in vitro and in vivo studies to evaluate the efficacy of a canine version of the DKK-1 inhibiting antisense morpholino (cDKKMO) in treating canine osteosarcoma. The research aims to determine if the...
The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 "Cancer Treatment Research" to The Johns Hopkins University to evaluate the safety and efficacy of the alpha-particle radiopharmaceutical therapy 225Ac-hu3F8 (A3F8) for the treatment of osteosarcoma. The $681,116 award, effective June 1, 2024 through May 31, 2029, will support experiments in a canine model of metastatic osteosarcoma to identify the maximum tolerated absorbed dose to the red marrow,...
This $394,482 federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop and validate demineralized bone paper (DBP)-based human bone metabolic and senolytic assays. The primary goals are to:
Develop humanized bone metabolic assays using DBP models seeded with human bone marrow-derived mesenchymal stem cells and CD14+ monocytes to mimic bone remodeling and validate the models with known anabolic and...
This $401,115 federal Project Grant, awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), will fund Georgetown University's development and validation of a 3D bioengineered microfluidic platform (3D-BMP) to model Ewing sarcoma bone metastasis. The 3D-BMP will mimic the bone microenvironment to enable high-throughput genomic screening and identify key drivers of Ewing sarcoma's spread to bone. The project aims to: 1) optimize the 3D-BMP to faithfully...